Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.
Serena Pillozzi,Andrea Bernini,Ilaria Palchetti,Olivia Crociani,Lorenzo Antonuzzo,D. A. Campanacci,Guido Scoccianti +6 more
Reads0
Chats0
TLDR
A comprehensive overview of the most relevant cellular, molecular and metabolic biomarkers for STS, and highlight advances in STS-related biomarker research can be found in this article and.Abstract:
Soft tissue sarcomas (STSs) are a heterogeneous group of rare tumors. Although constituting only 1% of all human malignancies, STSs represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. Over 100 histologic subtypes have been characterized to date (occurring predominantly in the trunk, extremity, and retroperitoneum), and many more are being discovered due to molecular profiling. STS mortality remains high, despite adjuvant chemotherapy. New prognostic stratification markers are needed to help identify patients at risk of recurrence and possibly apply more intensive or novel treatments. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the most relevant cellular, molecular and metabolic biomarkers for STS, and highlight advances in STS-related biomarker research.read more
Citations
More filters
Journal ArticleDOI
Retroperitoneal Sarcoma Care in 2021
Erika Schmitz,Carolyn Nessim +1 more
TL;DR: There have been considerable advancements in the understanding and treatment of retroperitoneal sarcoma in the last decade, with standard treatment consisting of upfront primary surgical resection for most subtypes.
Journal ArticleDOI
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
TL;DR: An up-to-date overview of the different immunotherapy modalities as potential treatments for sarcoma is provided, to identify barriers posed by the Sarcoma microenvironment to immunotherapy, highlight their relevance for impeding effectiveness, and suggest mechanisms to overcome these barriers.
Journal ArticleDOI
Chip-Based and Wearable Tools for Isothermal Amplification and Electrochemical Analysis of Nucleic Acids
Claudia Patiti,Patrick Severin Sfragano,Serena Laschi,Serena Pillozzi,Anna Boddi,Olivia Crociani,Andrea Bernini,Ilaria Palchetti +7 more
TL;DR: In this article , the authors summarize the different applications of isothermal amplification methods combined with electrochemical biosensing techniques in the development of lab-on-a-chip tools and wearable sensors.
Journal ArticleDOI
Metabolic landscapes in sarcomas.
TL;DR: In this article, the authors provide an update on the contribution of newly described mechanisms of metabolic regulation in soft tissue sarcomas and discuss how diverse metabolic landscapes condition the tumor microenvironment, anti-sarcoma immune responses and prognosis.
Journal ArticleDOI
Inflammatory leiomyosarcoma/rhabdomyoblastic tumor: A report of two cases with novel genetic findings
TL;DR: Next‐generation sequencing identified sequence variants in NF1, TP53, SMARCA4, KRAS, and MSH6 consistent with the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) syndrome in one of the study patients and suggestive that ILMS/IRT might be part of the HNPCC cancer spectrum.
References
More filters
Journal ArticleDOI
HMDB 4.0: the human metabolome database for 2018.
David S. Wishart,Yannick Djoumbou Feunang,Ana Marcu,An Chi Guo,Kevin Y. H. Liang,Rosa Vázquez-Fresno,Tanvir Sajed,Daniel Johnson,Carin Li,Naama Karu,Zinat Sayeeda,Elvis J. Lo,Nazanin Assempour,Mark V. Berjanskii,Sandeep Singhal,David Arndt,Yongjie Liang,Hasan Badran,Jason R. Grant,Arnau Serra-Cayuela,Yifeng Liu,Rupa Mandal,Vanessa Neveu,Allison Pon,Craig Knox,Michael Wilson,Claudine Manach,Augustin Scalbert +27 more
TL;DR: This year's update to the HMDB, HMDB 4.0, represents the most significant upgrade to the database in its history and should greatly enhance its ease of use and its potential applications in nutrition, biochemistry, clinical chemistry, clinical genetics, medicine, and metabolomics science.
Journal ArticleDOI
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers,Caitlin F. Connelly,David Fabrizio,Siraj M. Ali,Riley Ennis,Alexa B. Schrock,Brittany Campbell,Adam Shlien,Juliann Chmielecki,Franklin W. Huang,Yuting He,James Sun,Uri Tabori,Mark Kennedy,Daniel S. Lieber,Steven Roels,Jared White,G. Otto,Jeffrey S. Ross,Levi A. Garraway,Levi A. Garraway,Vincent A. Miller,Phillip J. Stephens,Garrett M. Frampton +23 more
TL;DR: Measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly, demonstrating that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy.
Journal ArticleDOI
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon,Theodore W. Laetsch,Shivaani Kummar,Steven G. DuBois,Ulrik Lassen,George D. Demetri,Michael J. Nathenson,Robert C. Doebele,Anna F. Farago,Alberto S. Pappo,Brian Turpin,Afshin Dowlati,Marcia S. Brose,Leo Mascarenhas,Noah Federman,Jordan Berlin,Wafik S. El-Deiry,Christina S. Baik,John F. Deeken,Valentina Boni,Ramamoorthy Nagasubramanian,Matthew H. Taylor,Erin R. Rudzinski,Funda Meric-Bernstam,Davendra Sohal,Patrick C. Ma,Luis E. Raez,Jaclyn F. Hechtman,Ryma Benayed,Marc Ladanyi,Brian B. Tuch,Kevin Ebata,Scott Cruickshank,Nora Ku,Michael C. Cox,Douglas S. Hawkins,David S. Hong,David S. Hong,David M. Hyman +38 more
TL;DR: Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type.
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Jonathan D. Oliner,Jennifer A. Pietenpol,Sam Thiagalingam,Jeno Gyuris,Kenneth W. Kinzler,Bert Vogelstein,Bert Vogelstein +6 more
TL;DR: It is shown that, when expressed in Saccharomyces cerevisiae, human MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that nearly coincides with the p53 acidic activation domain.
Related Papers (5)
Sarcoma treatment in the era of molecular medicine
Thomas G. P. Grunewald,Thomas G. P. Grunewald,Thomas G. P. Grunewald,Marta M. Alonso,Sofia Avnet,Ana Banito,Stefan Burdach,Florencia Cidre-Aranaz,Gemma Di Pompo,Martin Distel,Heathcliff Dorado-Garcia,Javier García-Castro,Laura González-González,Agamemnon E. Grigoriadis,Merve Kasan,Christian Koelsche,Manuela Krumbholz,Fernando Lecanda,Silvia Lemma,Dario Livio Longo,Claudia Madrigal-Esquivel,Alvaro Morales-Molina,Julian Musa,Julian Musa,Shunya Ohmura,Benjamin Ory,Miguel Pereira-Silva,Francesca Perut,Rene Rodriguez,Carolin Seeling,Nada Al Shaaili,Shabnam Shaabani,Kristina Shiavone,Snehadri Sinha,Eleni M. Tomazou,Marcel Trautmann,María Vela,Yvonne M.H. Versleijen-Jonkers,Julia D. Visgauss,Marta Zalacain,Sebastian J. Schober,Andrej Lissat,William R. English,Nicola Baldini,Dominique Heymann,Dominique Heymann +45 more